Genetic engineering and therapy for inherited and acquired cardiomyopathies

Annals of the New York Academy of Sciences

Volumn 1080, Issue , 2006, Pages 437-450

  Day, Sharlene ^a   Davis, Jennifer ^a   Westfall, Margaret ^a   Metzger, Joseph M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Gene delivery; Gene based therapies; Myofilament regulation; Sarcomere; Troponin I

Indexed keywords

ADENOVIRUS VECTOR; ISOPROTEIN; TROPONIN I;

CARDIOMYOPATHY; CARDIOVASCULAR GENE THERAPY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DRUG MECHANISM; GENE MUTATION; GENETIC ENGINEERING; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HYPERTROPHIC CARDIOMYOPATHY; MYOFILAMENT; NONHUMAN; PATHOGENESIS; PHENOTYPE; SARCOMERE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

EID: 33845639573     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1380.033     Document Type: Conference Paper

References (51)

1. THOM, T., N. HAASE, et al. 2006. Heart disease and stroke statistics-2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation.
2. MITK, A.M. 2006. Do lackluster trial findings mean new avenues are needed for heart research? JAMA 295: 611-612.
3. KATZ, A. 2001. Physiology of the Heart. Lippincott Williams and Wilkins. Philadelphia.
4. ORCHARD, C.H. & J.C. KENTISH. 1990. Effects of changes of pH on the contractile function of cardiac muscle. Am. J. Physiol. 258: C967-C981.
5. SOLARO, R.J., J.A. LEE, J.C. KENTISH & D.G. ALLEN 1988. Effects of acidosis on ventricular muscle from adult and neonatal rats. Circ. Res. 63: 779-787.
6. WESTFALL, M.V., E.M. RUST & J.M. METZGER 1997. Slow skeletal troponin I gene transfer, expression, and myofilament incorporation enhances adult cardiac myocyte contractile function. Proc. Natl. Acad. Sci. USA 94: 5444-5449.
7. 2+-activated myofilament tension in adult cardiac myocytes. Circ. Res. 86: 470-477.
8. REISER, P.J., M.V. WESTFALL, S. SCHIAFFINO & R.J. SOLARO 1994. Tension production and thin-filament protein isoforms in developing rat myocardium. Am. J. Physiol. 36: H1589-H1596.
9. NHLBI PROGRAM FOR GENOMIC APPLICATION. 2006. Genomics of Cardiovascular Development, Adaptation, and Remodeling. Harvard Medical School. Ref Type: Electronic Citation
10. WESTFALL, M.V & J.M. METZGER 2001. Troponin I isoforms and chimeras: tuning the molecular switch of cardiac contraction. News Physiol. Sci. 16: 278-281.
11. SAGGIN, L., L. GORZA, S. AUSONI & S. SCHIAFFINO. 1989. Troponin I switching in the developing heart. J. Biol. Chem. 264: 16299-16302.
12. HUNKELER, N.M., J. KULLMAN & A.M. MURPHY. 1991. Troponin I isoform expression in human heart. Circ. Res. 69: 1409-1414.
13. WOLSKA, B.M., K. VIJAYAN, G.M. ARTEAGA, et al. 2001. Expression of slow skeletal troponin I in adult transgenic mouse heart muscle reduces the force decline observed during acidic conditions. J. Physiol. 536: 863-870.
14. WESTFALL, M.V., I.I. TURNER, F.P. ALBAYYA & J.M. METZGER 2001. Troponin I chimera analysis of the cardiac myofilament tension response to protein kinase A. Am. J. Physiol. 280: C324-C332.
15. WESTFALL, M.V., F.P. ALBAYYA & J.M. METZGER 1999. Functional analysis of troponin I regulatory domains in the intact myofilament of adult single cardiac myocytes. J. Biol. Chem. 274: 22508-22516.
16. DAY, S.M., M.V. WESTFALL, et al. 2006. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat. Med. 12: 181-189.
17. TEERLINK, J.R. 2005. Overview of randomized clinical trials in acute heart failure syndromes. Am. J. Cardiol. 96: 59G-67G.
18. BAYRAM, M., L.L. DE, M.B. MASSIE & M. GHEORGHIADE. 2005. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am. J. Cardiol. 96: 47G-58G.
19. HOSHIJIMA, M. 2005. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol. Ther. 105: 211-228.
20. MARON, B.J. 2002. Hypertrophic cardiomyopathy: a systematic review. JAMA 287: 1308-1320.
21. MARON, B.J. 2003. Sudden death in young athletes. N. Engl. J. Med. 349: 1064-1075.
22. NISHIMURA, R.A. & D.R. HOLMES JR. 2004. Clinical practice. Hypertrophic obstructive cardiomyopathy. N. Engl. J. Med. 350: 1320-1327.
23. RICHARD, P., P. CHARRON, L. CARRIER, et al. 2003. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107: 2227-2232.
24. VAN DRIEST, S.L., S.R. OMMEN, et al. 2005. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin. Proc. 80: 463-469.
25. AHMAD, F., J.G. SEIDMAN & C.E. SEIDMAN. 2005. The genetic basis for cardiac remodeling. Annu. Rev. Genomics Hum. Genet. 6: 185-216.
26. BLAIR, E., C. REDWOOD, et al. 2001. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10: 1215-1220.
27. CHARRON, P., O. DUBOURG, et al. 1998. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein. C Gene Circ. 97: 2230-2236.
28. HO, C.Y.,H.M. LEVER, et al. 2000. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation 102: 1950-1955.
29. MARIAN, A.J. 2002. Modifier genes for hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 17: 242-252.
30. MICHELE, D.E., C.A. GOMEZ, K.E. HONG, et al. 2002. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ. Res. 92: 255-262.
31. FATKIN, D., B.K. MCCONNELL, et al. 2000. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106: 1351-1359.
32. SEMSARIAN, C., I. AHMAD, et al. 2002. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109: 1013-1020.
33. KNOLLMANN, B.C., P. KIRCHHOF, et al. 2003. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ. Res. 92: 428-436.
34. SPINDLER, M., K.W. SAUPE, et al. 1998. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J. Clin. Invest. 101: 1775-1783.
35. JAVADPOUR, M.M., J.C. TARDIFF, I. PINZ & J.S. INGWALL 2003. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J. Clin. Invest. 112: 768-775.
36. FATKIN, D. & R.M. GRAHAM. 2002. Molecular mechanisms of inherited cardiomyopathies. Physiol. Rev. 82: 945-980.
37. KAMISAGO, M., S.D. SHARMA, et al. 2000. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343: 1688-1696.
38. DAEHMLOW, S., J. ERDMANN, et al. 2002. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298: 116-120.
39. CHANG, A.N., K. HARADA, M.J. ACKERMAN & J.D. POTTER. 2005. Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin. J. Biol. Chem. 280: 34343-34349.
40. MIRZA, M., S. MARSTON, et al. 2005. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J. Biol. Chem. 280: 28498-28506.
41. KUSHWAHA, S.S., J.T. FALLON & V. FUSTER. 1997. Restrictive cardiomyopathy. N. Engl. J. Med. 336: 267-276.
42. MOGENSEN, J., R. KUBO, et al. 2003. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111: 209-216.
43. GOMES, A.V., J. LIANG & J.D. POTTER. 2005. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J. Biol. Chem. 280: 30909-30915.
44. YUMOTO, F., Q.W. LU, et al. 2005. Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem. Biophys. Res. Commun. 338: 1519-1526.
45. HAGHIGHI, K., K.N. GREGORY & E.G. KRANIAS. 2004. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 322: 1214-1222.
46. SZATKOWSKI, M.L., M.V. WESTFALL, et al. 2001. In vivo acceleration of heart relaxation performance by Parvalbumin gene delivery. J. Clin. Invest. 107: 191-198.
47. ROTHERMEL, B.A., T.A. MCKINSEY, R.B. Vega, et al. 2001. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 98: 3328-3333.
48. SUSSMAN, M.A., H.W. LIM, N. GUDE, et al. 1998. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281: 1690-1693.
49. ZHANG, R., M.S. KHOO, Y. WU, et al. 2005. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11: 409-417.
50. ROBBINS, J. 2000. Remodeling the cardiac sarcomere using transgenesis. Annu. Rev. Physiol. 62: 261-287.
51. MICHELE, D.E., F. ALBAYYA & J.M. METZGER 1999. Thin filament protein dynamics in fully differentiated adult cardiac myocytes: toward a model of sarcomere maintenance. J. Cell. Biol. 145: 1483-1495.